📊 COR Key Takeaways
Investment Thesis
Cencora operates in a capital-intensive wholesale pharmaceuticals sector with critically weak operational cash flow (-$2.3B) and negative free cash flow (-$2.4B), indicating the company is burning cash despite $85.9B in revenue. The extremely thin operating margin of 0.9% combined with high leverage (4.15x debt-to-equity) and a current ratio below 1.0x creates significant financial stress and sustainability concerns.
COR Strengths
- Exceptionally high ROE of 29.3% demonstrates efficient use of equity capital
- Strong gross profit of $3.1B on large revenue base shows core business generates absolute earnings
- Substantial asset base of $78.4B provides scale and operational infrastructure
COR Risks
- Severe negative operating cash flow of -$2.3B signals the business model is not generating cash despite profitability on paper
- Critical liquidity concerns with current ratio of 0.92x and quick ratio of 0.51x indicating difficulty meeting short-term obligations
- Unsustainable debt burden with 4.15x debt-to-equity ratio and $7.9B long-term debt relative to only $1.9B equity cushion
Key Metrics to Watch
- Operating Cash Flow trend - must turn positive to demonstrate sustainable business
- Debt-to-Equity ratio - target reduction below 2.5x for financial stability
- Current Ratio improvement - needs to exceed 1.2x to ensure adequate liquidity
COR Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
COR Profitability Ratios
COR vs Default Sector
How Cencora, Inc. compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
COR Balance Sheet & Liquidity
COR 5-Year Financial Trend
5-Year Trend Summary: Cencora, Inc.'s revenue has grown significantly by 50% over the 5-year period, indicating strong business expansion. The most recent EPS of $8.53 reflects profitable operations.
COR Growth Metrics (YoY)
COR Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $81.5B | $488.6M | $2.50 |
| Q3 2025 | $74.2B | $483.5M | $2.42 |
| Q2 2025 | $68.4B | $420.8M | $2.09 |
| Q1 2025 | $72.3B | $488.6M | $2.50 |
| Q3 2024 | $66.9B | $479.6M | $2.35 |
| Q2 2024 | $63.5B | $420.8M | $2.09 |
| Q1 2024 | $62.8B | $479.7M | $2.33 |
| Q3 2023 | $60.1B | $407.0M | $1.92 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
COR Capital Allocation
COR SEC Filings
Access official SEC EDGAR filings for Cencora, Inc. (CIK: 0001140859)
📋 Recent SEC Filings
❓ Frequently Asked Questions about COR
What is the AI rating for COR?
Cencora, Inc. (COR) has an AI rating of SELL with 75% confidence, based on fundamental analysis of SEC EDGAR filings.
What are COR's key strengths?
Exceptionally high ROE of 29.3% demonstrates efficient use of equity capital. Strong gross profit of $3.1B on large revenue base shows core business generates absolute earnings.
What are the risks of investing in COR?
Severe negative operating cash flow of -$2.3B signals the business model is not generating cash despite profitability on paper. Critical liquidity concerns with current ratio of 0.92x and quick ratio of 0.51x indicating difficulty meeting short-term obligations.
What is COR's revenue and growth?
Cencora, Inc. reported revenue of $85.9B.
Does COR pay dividends?
Cencora, Inc. pays dividends, with $126.5M distributed to shareholders in the trailing twelve months.
Where can I find COR SEC filings?
Official SEC filings for Cencora, Inc. (CIK: 0001140859) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is COR's EPS?
Cencora, Inc. has a diluted EPS of $2.87.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.